Navigation

Proposed Technology Appraisals

These are the topics which the National Institute for Health and Care Excellence has been invited to appraise. For each proposed appraisal, the table gives the suggested remit, the dates of the consultation on that remit, an e-mail address to send any enquiries to regarding the proposed appraisal, and links to any documents being consulted on in addition to the suggested remit.

Topic Multiple myeloma (relapsed, refractory) - panobinostat
Suggested remit To appraise the clinical and cost effectiveness of panobinostat within its licensed indication for treating relapsed and refractory multiple myeloma previously treated with bortezomib.
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators 12 March 2014 - 10 April 2014
Batch 36
Scoping workshop Friday 9 May 2014 (afternoon) London
Enquiries to michelle.adhemar@nice.org.uk
Consultation document(s)

Draft scope

Provisional matrix

back to top

Topic Leukaemia (chronic lymphocytic) - ofatumumab (maintenance)
Suggested remit To appraise the clinical and cost effectiveness of ofatumumab within its licensed indication for the maintenance treatment of relapsed chronic lymphocytic leukaemia.
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators 12 March 2014 - 10 April 2014
Batch 36
Scoping workshop Friday 9 May 2014 (morning) London
Enquiries to michelle.adhemar@nice.org.uk
Consultation document(s)

Draft scope

Provisional matrix

back to top

Topic Venous thromboembolism (treatment, secondary prevention) - edoxaban tosylate
Suggested remit To appraise the clinical and cost effectiveness of edoxaban tosylate within its licensed indication for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism.
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators 12 March 2014 - 10 April 2014
Batch 36
Scoping workshop Thursday 8 May 2014 (morning) London
Enquiries to michelle.adhemar@nice.org.uk
Consultation document(s)

Draft scope

Provisional matrix

back to top

Topic: Ovarian, fallopian tube, peritoneal cancer (relapsed, platinum sensitive, BRCA 1 or 2 mutations) - olaparib (maintenance) [ID735]
Suggested remit To appraise the clinical and cost effectiveness of naltrexone-bupropion prolonged release within its licensed indication for treating adults who are overweight or obese.
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators 6 March 2014 - 4 April 2014
Batch 36
Scoping workshop Friday 2 May 2014 (afternoon) in London
Enquiries to michelle.adhemar@nice.org.uk
Consultation document(s)

Draft scope

Provisional matrix

back to top

Topic Lung cancer (non-small cell, anaplastic lymphoma kinase positive, metastatic) - LDK378 (post chemotherapy)
Suggested remit To appraise the clinical and cost effectiveness of LDK378 within its licensed indication for previously treated anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators 5 March 2014 - 3 April 2014
Batch Thursday 1 May 2014 (morning) in London
Scoping workshop michelle.adhemar@nice.org.uk
Enquiries to

Draft scope

Provisional matrix

Consultation document(s) Thursday 1 May 2014 (afternoon) in London

back to top

Topic: Obesity - naltrexone-bupropion (prolonged release) [ID 757]
Suggested remit To appraise the clinical and cost effectiveness of naltrexone-bupropion prolonged release within its licensed indication for treating adults who are overweight or obese.
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators 5 March 2014 - 3 April 2014
Batch 36
Scoping workshop Thursday 1 May 2014 (morning) in London
Enquiries to michelle.adhemar@nice.org.uk
Consultation document(s)

Draft scope

Provisional matrix

back to top

Topic Malignant melanoma - ipilimumab - ID721
Suggested remit To appraise the clinical and cost effectiveness of ipilimumab within its licensed indication for the adjuvant treatment of completely resected high risk stage III or IV melanoma.
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators 24 January 2014 - 21 February 2014
Batch 35
Scoping workshop Friday 14 March 2014 (afternoon) in Manchester
Enquiries to michelle.adhemar@nice.org.uk
Consultation document(s)

Draft scope

Provisional matrix

back to top

Topic Non-Hodgkin's lymphoma - idelalisib in combination with rituximab - ID723
Suggested remit To appraise the clinical and cost effectiveness of idelalisib within its licensed indication for refractory indolent non-Hodgkin's lymphoma.
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators 27 January 2014 - 24 February 2014
Batch 35
Scoping workshop Monday 17 March 2014 (morning) in London
Enquiries to michelle.adhemar@nice.org.uk
Consultation document(s)

Draft scope

Provisional matrix

back to top

Topic Mantle cell lymphoma - lenalidomide - ID739
Suggested remit To appraise the clinical and cost effectiveness of lenalidomide within its licensed indication for treating relapsed or refractory mantle cell lymphoma.
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators 27 January 2014 - 24 February 2014
Batch 35
Scoping workshop Monday 17 March 2014 (afternoon) in London
Enquiries to michelle.adhemar@nice.org.uk
Consultation document(s)

Draft scope

Provisional matrix

back to top

Topic Atrial fibrillation (non-valvular, stroke and embolism prevention) - edoxaban tosylate - ID624
Suggested remit To appraise the clinical and cost effectiveness of edoxaban tosylate within its licensed indication for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation.
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators 28 January 2014 - 25 February 2014
Batch 35
Scoping workshop Tuesday 18 March 2014 (morning) in London
Enquiries to michelle.adhemar@nice.org.uk
Consultation document(s)

Draft scope

Provisional matrix

back to top

Topic Venous thromboembolic events (prevention) - apixaban - ID726
Suggested remit To appraise the clinical and cost effectiveness of apixaban within its licensed indication for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism.
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators 29 January 2014 - 26 February 2014
Batch 35
Scoping workshop Wednesday 26 March 2014 (morning) in London
Enquiries to michelle.adhemar@nice.org.uk
Consultation document(s)

Draft scope

Provisional matrix

back to top

This page was last updated: 26 March 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.